Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth

Hormone Research

Volumn 68, Issue 5, 2007, Pages 209-217

  Harwood, Katerina ^a   Vuguin, Patricia ^a   DiMartino Nardi, Joan ^a,b  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Life style changes; Ovarian ultrasound; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANDROSTENEDIONE; ANTIANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FINASTERIDE; FLUTAMIDE; GESTAGEN; GESTODENE; GLUCOCORTICOID; INSULIN; INSULIN SENSITIZING AGENT; LEVONORGESTREL; LUTEINIZING HORMONE; METFORMIN; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; PREDNISONE; PROGESTERONE DERIVATIVE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE;

ACANTHOSIS NIGRICANS; ACNE; ANAMNESIS; ANDROSTENEDIONE BLOOD LEVEL; ANOVULATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDUCED HEADACHE; ECHOGRAPHY; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; ESTHETIC SURGERY; EXERCISE; FAMILY HISTORY; FATIGUE; GASTRITIS; GENETIC DISORDER; GONADOTROPIN RELEASE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOPHYSIS FUNCTION; HYPOPHYSIS GONAD SYSTEM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; JUVENILE; LIFESTYLE MODIFICATION; MENARCHE; MENSTRUATION; METABOLISM; NAUSEA; OBESITY; ONSET AGE; OVARY CYST; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHYSICAL EXAMINATION; POLYDIPSIA; POLYURIA; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; SCREENING TEST; SHORT SURVEY; SKIN MANIFESTATION; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WEIGHT REDUCTION;

ADOLESCENT; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME;

EID: 34948822883     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101538     Document Type: Short Survey

References (57)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
2. Kent SC, Legro RS: Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73-88, vi.
3. Meas T, Chevenne D, Thibaud E, Leger J, Cabrol S, Czernichow P, Levy-Marchal C: Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clin Endocrinol (Oxf) 2002;57:101-106.
4. Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E: Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1599-1603.
5. Dimartino-Nardi J: Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl 1999;88:67-72.
6. Vuguin P, Linder B, Rosenfeld RG, Saenger P, DiMartino-Nardi J: The roles of insulin sensitivity, insulin-like growth factor I (IGFI), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche. J Clin Endocrinol Metab 1999;84:2037-2042.
7. Ibanez L, Potau N, Francois I, de Zegher F: Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-3562.
8. McNatty KP, Makris A, DeGrazia C, Osathanondh R, Ryan KJ: The production of progesterone, androgens, and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab 1979;49:687-699.
9. Berga SL, Guzick DS, Winters SJ: Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab 1993;77:895-901.
10. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC: Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
11. Turgeon JL, Waring DW: Androgen modulation of luteinizing hormone secretion by female rat gonadotropes. Endocrinology 1999;140:1767-1774.
12. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-353.
13. Rosenfield RL: Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin N Am 1999;28:265-293.
14. Buggs C, Rosenfield RL: Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin N Am 2005;34:677-705, x.
15. Longcope C: Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986;15:213-228.
16. Edmunds SE, Stubbs AP, Santos AA, Wilkinson ML: Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line. J Steroid Biochem Mol Biol 1990;37:733-739.
17. Penttila TL, Koskinen P, Penttila TA, Anttila L, Irjala K: Obesity regulates bioavailable testosterone levels in women with or without polycystic ovary syndrome. Fertil Steril 1999;71:457-461.
18. Gilling-Smith C, Story H, Rogers V, Franks S: Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93-99.
19. Pang S: Pediatric Endocrinology, ed 4. New York, Marcel Dekker, 2003.
20. Franks S, Gilling-Smith C, Watson H, Willis D: Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin N Am 1999;28:361-378.
21. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001-2005.
22. Willis D, Franks S: Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-3790.
23. Loukovaara M, Carson M, Adlercreutz H: Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. J Clin Endocrinol Metab 1995;80:160-164.
24. Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-497.
25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
26. Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830.
27. Moll GW Jr, Rosenfield RL: Testosterone binding and free plasma androgen concentrations under physiological conditions: characterization by flow dialysis technique. J Clin Endocrinol Metab 1979;49:730-736.
28. Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR: Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol 1983;146:602-606.
29. Goodman NF, Bledsoe MB, Futterweit W, Goldzieher JW, Petak SM, Smith KD, Steinberger E, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA: American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract 2001;7:120-134.
30. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, Neubauer G, Klibanski A: Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 2004;89:525-533.
31. Blethen SL, Chasalow FI: Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids 1989;54:185-193.
32. Azziz R, Dewailly D, Owerbach D: Clinical review 56. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994;78:810-815.
33. Lewy VD, Danadian K, Witchel SF, Arslanian S: Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001;138:38-44.
34. Rosenfield RL, Ghai K, Ehrmann DA, Barnes RB: Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 2000;13(suppl 5):1285-1289.
35. Salmi DJ, Zisser HC, Jovanovic L: Screening for and treatment of polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood) 2004;229:369-377.
36. Huber-Buchholz MM, Carey DG, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-1474.
37. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS: A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-429.
38. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-819.
39. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS: A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;81:630-637.
40. Lidegaard O: Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995;102:153-159.
41. Lloyd T, Lin HM, Matthews AE, Bentley CM, Legro RS: Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol 2002;100:235-239.
42. Deplewski D, Rosenfield RL: Role of hormones in pilosebaceous unit development. Endocr Rev 2000;21:363-392.
43. Ibanez L, Potau N, Marcos MV, de Zegher F: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-3255.
44. van Wayjen RG, van den Ende A: Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103:241-251.
45. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F: Spironolactone as a single agent for longterm therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52:587-594.
46. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G: Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141:361-367.
47. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
48. Farquhar C, Lee O, Toomath R, Jepson R: Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003:CD000194.
49. Balfour JA, McClellan K: Topical eflornithine. Am J Clin Dermatol 2001;2:197-201; discussion 202.
50. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 2002;137:25-33.
51. Arslanian SA, Lewy V, Danadian K, Saad R: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-1559.
52. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L: Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002;16:217-224.
53. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000;85:3526-3530.
54. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L: Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-169.
55. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-3598.
56. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, De Zegher F: Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004;89:4331-4337.
57. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-1218.